BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
To create leading company developing medicines targeting metalloenzymes
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Cipla and Ethris partner for the development of mRNA-based therapies
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Subscribe To Our Newsletter & Stay Updated
